Enanta Pharmaceuticals | ENTA - Operating Profit


Enanta Pharmaceuticals reported $-23.54M in Operating Profit for its fiscal quarter ending in December of 2024.





Operating Profit Change Date
AbbVie USD 6.88B 156M Sep/2026
Amgen USD 4.68B 65M Sep/2026
Anika Therapeutics USD 646K 3.88M Dec/2025
Arrowhead Research USD -170.09M 28.83M Jun/2026
AstraZeneca USD 4.66B 1.5B Sep/2026
BioCryst Pharmaceuticals USD 98.46M 161.92M Jun/2026
Biogen USD 419.5M 663.3M Sep/2026
Bristol-Myers Squibb USD 255M 44M Sep/2026
Enanta Pharmaceuticals USD -23.54M 98.15M Dec/2024
Gilead Sciences USD 3.85B 1.17B Jun/2026
GlaxoSmithKline GBP 2.86B 251M Sep/2026
Halozyme Therapeutics USD -60.68M 3.04M Sep/2026
Heron Therapeutics USD 38K 3.83M Dec/2025
Immunic USD -23.33M 2.67M Dec/2025
Incyte USD -707.47M 1.41B Sep/2026
Insmed USD -81.83M 19.48M Sep/2026
Ionis Pharmaceuticals USD -102.29M 15.71M Jun/2026
J&J USD 6.47B 1B Sep/2026
Karyopharm Therapeutics USD -26.76M 8.92M Mar/2026
Ligand Pharmaceuticals USD 54.53M 2.1M Sep/2026
Merck USD 7.33B 6.49B Sep/2026
Neurocrine Biosciences USD 343M 123.1M Sep/2026
Novartis USD 5.14B 392M Sep/2026
Novavax USD 20.94M 100.32M Dec/2025
Pfizer USD 662M 5M Sep/2026
PTC Therapeutics USD 148.98M 103.09M Jun/2026
Roche Holding CHF 11.46B 1.91B Jun/2026
Sarepta Therapeutics USD -9.04M 22.33M Sep/2026
Vertex Pharmaceuticals USD 1.26B 11.3M Sep/2026